Safety profile of WinRho anti-D.
WinRho anti-D is manufactured with multiple processes to minimize the risk of transmitting blood-borne diseases such as viruses. These safety features include donor selection, plasma testing, solvent-detergent viral inactivation, and nanofiltration. To date, there has not been any case of viral transmission in association with use of WinRho anti-D. Adverse drug reactions are infrequent and generally mild; the most common are headache, fever, and chills. Some degree of hemolysis is inevitable due to the mechanism of action of WinRho anti-D, but this is predictable and transient. A few cases of intravascular hemolysis have been reported; hypersensitivity reactions are very rare. WinRho anti-D has been shown in both clinical trials and postmarketing surveillance to be safe and effective in the treatment of idiopathic thrombocytopenic purpura (ITP) and in the prevention of Rh isoimmunization.
Hong
F
F
Nabi, Rockville, MD 20852, USA.
Ruiz
R
R
Price
H
H
Griffiths
A
A
Malinoski
F
F
Woloski
M
M
D004342:Drug Hypersensitivity / Q000209:etiology; D004358:Drug Therapy / Q000592:standards*; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D012203:Rh Isoimmunization / Q000517:prevention & control; D018029:Rho(D) Immune Globulin / Q000009:adverse effects / Q000627:therapeutic use*; D012449:Safety; D014777:Virus Diseases / Q000635:transmission
D018029:Rho(D) Immune Globulin